YOKNEAM, Israel – May 8, 2026
Lumenis announced that its groundbreaking hair restoration platform FoLix™ has received the Hair Loss Technology Innovation Award at the 2025 Medical Device Network Excellence Awards, recognizing the company’s leadership in advancing non-invasive medical technologies for hair loss treatment. The award highlights growing industry recognition for FoLix™, the first FDA-cleared non-ablative fractional laser (NAFL) technology designed specifically for hair loss treatment, as demand continues rising for clinically validated and minimally invasive aesthetic medical solutions.
The Medical Device Network Excellence Awards recognize major achievements and technological innovations across the global medical device industry. Powered by GlobalData’s business intelligence platform, the awards focus on companies and technologies driving significant change in healthcare innovation, patient care and medical technology advancement. Lumenis stated that the award validates the company’s efforts to create safer, more accessible and scientifically supported solutions for patients experiencing hair thinning and hair loss.
FoLix™ Introduces New Standard in Hair Restoration
Hair loss affects more than 80 million people in the United States alone, creating significant emotional and psychological impact for patients worldwide. Existing treatment options often present challenges related to inconsistent efficacy, invasive surgical procedures, side effects or long recovery periods. Lumenis developed FoLix™ as a non-invasive alternative designed to improve scalp hair growth without surgery or downtime.
FoLix™ uses Lumenis’ proprietary non-ablative fractional laser (NAFL) technology to create controlled microscopic thermal zones within the skin, stimulating the body’s natural healing response and activating hair follicle regeneration. According to the company, the treatment protocol typically involves four to six monthly sessions followed by periodic maintenance treatments several times per year to sustain results. Each procedure is designed to be quick, comfortable and minimally disruptive for patients.
Advertisement
Lumenis Chief Executive Officer Tzipi Ozer-Armon stated that hair loss can significantly affect self-confidence and quality of life, emphasizing that the company is honored to have FoLix™ recognized as a leading innovation in the field of restorative hair treatment. She noted that the FDA-cleared device represents a major advancement in non-invasive hair restoration technologies designed for both male and female patients.
Clinical Data Demonstrates Hair Regeneration Potential
The company highlighted extensive preclinical and clinical evidence supporting the effectiveness and safety profile of FoLix™ technology. Preclinical studies demonstrated that NAFL treatment stimulates key biological pathways involved in hair follicle development and regeneration, including activation of the Sonic Hedgehog (SHH) and Wnt/B-catenin signaling pathways, both considered critical regulators of hair growth.
Clinical studies involving human patients also generated encouraging results. In a retrospective review involving 98 patients aged 21 to 66, independent board-certified dermatologists correctly identified before-and-after treatment images in nearly 97% of cases, demonstrating visible scalp hair improvement following treatment. Both male and female participants experienced measurable increases in hair count and follicular unit density without reported adverse events during or after treatment.
Lumenis emphasized that the technology’s strong safety profile and statistically significant treatment outcomes position FoLix™ as an important advancement within the rapidly growing field of energy-based aesthetic and dermatologic medical devices.
Strategic Partnerships Drive Global Expansion
The company reported that FoLix™ has rapidly expanded across North America, the Middle East and Asia-Pacific markets through partnerships with leading dermatologists, hair restoration clinics and academic institutions. Collaborations with organizations including Bosley, NYU Dermatology Department, Bauman Medical and internationally recognized specialists have accelerated clinical adoption and physician awareness.
Lumenis stated that it continues investing in future digital health technologies, remote connectivity and smart medical device ecosystems aimed at improving clinical efficiency and patient outcomes. The company believes FoLix™ represents the beginning of a broader strategy to expand AI-enabled and energy-based treatment innovations across multiple therapeutic and aesthetic indications.
As global demand for non-surgical hair restoration continues increasing, Lumenis’ recognition at the 2025 Medical Device Network Excellence Awards reinforces the company’s growing influence within the evolving medical aesthetics and dermatology technology markets.
Source: Lumenis press release
